Harrow (HROW) Research & Development (2010 - 2026)
Harrow (HROW) posted Research & Development of $8.1 million for Q2 2026, up 36.93% on a QoQ basis from $5.9 million in Q1 2026, and up 181.45% year-over-year from $2.9 million in Q2 2025.
Analysis
Harrow (HROW) Research & Development (2010 - 2026) Analysis & Trends
Harrow has reported Research & Development for 17 years, with the latest figure at $8.1 million in Q2 2026.
- On a quarterly basis, Research & Development rose 181.45% year-over-year to $8.1 million in Q2 2026; TTM through Jun 2026 was $29.0 million, a 124.52% increase from a year earlier, with the FY2025 full-year figure at $20.9 million, up 71.22% from the prior year.
- Research & Development was $8.1 million for Q2 2026 at Harrow, up from $5.9 million in the prior quarter.
- The five-year high for Research & Development was $11.7 million in Q4 2025, with the low at $658000.0 in Q1 2022.
- Average Research & Development over 5 years is $3.2 million, with a median of $2.6 million recorded in 2024.
- The sharpest annual moves came in 2022 and 2023: Research & Development slumped 87.35% in 2022, then soared 374.54% in 2023.
- Over 5 years, Research & Development stood at $703000.0 in 2022, then soared by 374.54% to $3.3 million in 2023, then jumped by 42.54% to $4.8 million in 2024, then jumped by 146.54% to $11.7 million in 2025, then sank by 31.14% to $8.1 million in 2026.
- The last three Research & Development figures came in at $8.1 million (Q2 2026), $5.9 million (Q1 2026), and $11.7 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.70 Bn | 621.95 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 440.80 Bn | 434.23 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 266.37 Bn | 258.68 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Pfizer | 158.89 Bn | 147.19 Bn | 10.94 Bn | 2.81 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | -2.60 Bn |
| 7 | Revolution Medicines | 44.38 Bn | 44.38 Bn | - | 394.92 Mn |
| 8 | Incyte | 25.28 Bn | 20.74 Bn | 1.57 Bn | 516.95 Mn |
| 9 | United Therapeutics | 21.46 Bn | 18.80 Bn | 683.80 Mn | 146.30 Mn |
| 10 | Harrow | 1.41 Bn | 1.32 Bn | 50.36 Mn | 8.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8.07 Mn |
| Mar 31, 2026 | 5.90 Mn |
| Dec 31, 2025 | 11.72 Mn |
| Sep 30, 2025 | 3.32 Mn |
| Jun 30, 2025 | 2.87 Mn |
| Mar 31, 2025 | 3.03 Mn |
| Dec 31, 2024 | 4.76 Mn |
| Sep 30, 2024 | 2.27 Mn |
| Jun 30, 2024 | 3.05 Mn |
| Mar 31, 2024 | 2.15 Mn |
| Dec 31, 2023 | 3.34 Mn |
| Sep 30, 2023 | 1.42 Mn |
| Jun 30, 2023 | 1.16 Mn |
| Mar 31, 2023 | 734,000.00 |
| Dec 31, 2022 | 703,000.00 |
| Sep 30, 2022 | 775,000.00 |
| Jun 30, 2022 | 914,000.00 |
| Mar 31, 2022 | 658,000.00 |
| Dec 31, 2021 | 3.94 Mn |
| Sep 30, 2021 | 6.13 Mn |